Diagnos Laboratorium Utama PT Tbk

DGNS · JK · Healthcare / Diagnostics & Research

290.00IDR+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close290.00

Open290.00

Day Range290.00 – 294.00

52-Week Range136.00 – 382.00

Volume103.00K

Market Cap390.50B

P/E (TTM)5.48

Forward P/E0.00

EPS51.84

Dividend Yield0.00%

Beta0.41

50-Day Avg250.16

200-Day Avg257.68

About

PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers laboratory tests comprising hemostasis, hepatitis, autoimmune and rheumatology, tumor markers, toxicology, lipid, allergies, TORCH, diabetes, electrolytes-blood gases, respiratory tract infection, pathology anatomy, neonatal screening, hematology, body fluids, feces, specific proteins, DNAnswer genomics, kidney function, liver function, immunology, osteoporosis, thyroid, pharmacogenomic, heart, reproduction and fertility, microbiology, drug monitoring, lungs, gastrointestinal, nutrition and heavy metals, anemia, and other bacteria; genomics; homecare services; and inspection panel tests. It also provides clinical pathology, anatomical pathology, and microbiology laboratory; and corporate health and research services. PT Diagnos Laboratorium Utama Tbk was founded in 2007 and is headquartered in Jakarta Pusat, Indonesia.

Company Details

SectorHealthcare
IndustryDiagnostics & Research
CEOMr. Fergus Richard
Employees87
HeadquartersGedung Graha Anam, Jakarta Pusat, Indonesia, 1500358, Indonesia
Websitehttps://diagnos.co.id

Leadership

Mr. Fergus RichardPresident Director · b. 1993
Antony SubagiaOperational Director & Director
Mr. Martinus Eliatulo ZegaGM of Sales & Independent Commissioner · b. 1971
Maurina DwiyanthiHead of Internal Audit Unit & Manager of SPI · b. 1992
Mr. Fanfan RiksaniCorporate Secretary · b. 1977
Mr. Stefanus IvanlyCorporate Secretary

Financials

Income Statement

Currency: IDR	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	14.01B	38.55B	51.34B	183.17B	302.18B	192.89B	145.70B	163.07B	166.62B
Growth (%)	-	+175.10%	+33.16%	+256.80%	+64.97%	-36.17%	-24.47%	+11.93%	+2.18%
Cost of Revenue	9.31B	22.02B	31.85B	97.27B	154.54B	104.49B	86.38B	98.59B	95.01B
Gross Profit	4.70B	16.53B	19.49B	85.90B	147.64B	88.40B	59.31B	64.49B	71.61B
Gross Margin	33.56%	42.89%	37.95%	46.90%	48.86%	45.83%	40.71%	39.54%	42.98%
Operating Expense	2.76B	4.10B	6.28B	18.87B	66.37B	70.74B	73.34B	62.27B	66.53B
Operating Income	1.94B	12.44B	13.20B	67.03B	81.28B	17.66B	-14.03B	2.22B	5.08B
Operating Margin	13.84%	32.26%	25.72%	36.59%	26.90%	9.15%	-9.63%	1.36%	3.05%
EBITDA	1.85B	12.64B	14.90B	70.82B	90.84B	31.39B	1.53B	16.63B	16.40B
EBITDA Margin	13.20%	32.78%	29.02%	38.66%	30.06%	16.27%	1.05%	10.20%	9.84%
Net Income	1.38B	9.26B	9.27B	52.69B	64.30B	12.66B	-13.66B	747.44M	2.94B
Net Income Margin	9.86%	24.03%	18.07%	28.76%	21.28%	6.57%	-9.37%	0.46%	1.76%
R&D	-	-	425.89M	593.36M	273.57M	586.17M	249.04M	759.20M	857.41M
R&D as % of Total Revenue	-	-	0.83%	0.32%	0.09%	0.30%	0.17%	0.47%	0.51%
Interest Expense	0	0	0	0	0	817.98M	475.24M	881.83M	775.60M
Interest Expense % of Total Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.42%	0.33%	0.54%	0.47%

Balance Sheet

Currency: IDR	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	8.49B	24.44B	59.22B	132.57B	241.98B	239.94B	271.48B	300.02B	318.67B
Total Liabilities	5.27B	11.17B	12.76B	33.51B	40.18B	29.51B	75.88B	103.89B	114.68B
Total Equity	3.22B	13.27B	46.46B	99.07B	201.80B	210.43B	195.59B	196.13B	203.99B
Cash	1.30B	1.54B	1.39B	16.54B	44.72B	28.01B	10.24B	4.21B	8.47B
Total Debt	112.81M	5.22B	3.69B	2.95B	13.42B	21.47B	56.76B	72.09B	79.25B
Net Debt	-1.19B	3.69B	2.10B	-14.26B	-38.28B	-13.32B	40.76B	67.88B	70.77B

Cash Flow

Currency: IDR	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-712.00M	8.47B	11.20B	26.23B	58.87B	-6.02B	13.18B	27.30B	10.66B
Investing Cash Flow	-1.04B	-6.46B	-29.24B	-8.15B	-75.57B	-17.55B	-42.39B	-44.18B	-8.59B
Financing Cash Flow	1.76B	-1.77B	17.90B	-2.93B	44.87B	6.86B	11.44B	10.85B	2.20B
Capital Expenditure	327.48M	3.84B	2.78B	5.86B	67.84B	34.85B	38.32B	43.39B	8.07B
Free Cash Flow	-1.04B	4.63B	8.41B	20.36B	-8.97B	-40.87B	-25.14B	-16.10B	2.58B
Dividends Paid	-	6.00B	6.00B	6.00B	6.00B	0	-	-	-
FCF to OCF	145.99%	54.69%	75.15%	77.64%	-15.23%	679.35%	-190.70%	-58.96%	24.25%
Dividend Paid to FCF	-	129.55%	71.31%	29.46%	-66.92%	0.00%	-	-	-

Earnings

Report Date	Mar 31, 2021	Jun 30, 2021	Sep 30, 2021	Dec 31, 2021	Mar 31, 2022	Jun 30, 2022	Sep 30, 2022	Dec 31, 2022	Mar 31, 2023	Jun 30, 2023
EPS Estimate	-	-	-	-	-	-	-	-	-	-
EPS Actual	17.44	19.44	14.31	0.26	6.72	1.62	1.39	0.40	-2.77	-3.42
Surprise	-	-	-	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap390.50B

Enterprise Value346.50B

Trailing P/E5.48

Forward P/E0.00

Price / Sales2.21

Price / Book0.00

EPS51.84

Book Value167.43

Revenue (TTM)176.49B

Gross Profit (TTM)83.69B

EBITDA13.93B

Profit Margin1.16%

Operating Margin-3.40%

Return on Equity0.96%

Return on Assets1.09%

Shares Outstanding1.38B

Shares Float412.17M

Beta0.41

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Dividends

20211×

4.80Aug 6, 2021